| Erin Dover, LICSW | |
|
1909 Commerce Ave, Cullman, AL 35055-6151 | |
| (256) 734-4688 | |
| Not Available |
| Full Name | Erin Dover |
|---|---|
| Gender | Female |
| Speciality | Clinical Social Worker |
| Experience | 7 Years |
| Location | 1909 Commerce Ave, Cullman, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013426295 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wellstone, Inc. | 9739070046 | 15 |
News Archive
Asynt has introduced new reaction inserts for its DrySyn Heating Block range enabling scientists to now conduct precisely controlled heated/stirred experiments in 3 Dram vials, 20ml Scintillation vials and 2ml HPLC sample vials. The new multi position blocks when combined with a DrySyn base unit allow up to 27 experiments to be performed in parallel.
Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer.
The ability to tactually recognize fine spatial details, such as the raised dots used in braille, is especially important to those who are blind.
A team of researchers led by Kath Bogie, DPhil (PhD), a biomedical engineer and associate professor of orthopaedics and biomedical engineering at Case Western Reserve University School of Medicine, and colleagues from Case Western Reserve and other institutions, has received a $1.8M, three-year grant from the U.S. Department of Defense to develop an implantable muscle stimulator for preventing pressure ulcers and deep tissue injuries to the buttocks.
Elan Corporation, plc and Transition Therapeutics, Inc today announced the results of a Phase 2 placebo-controlled study in 351 patients with mild to moderate Alzheimer's disease who received study drug for up to 18 months (Study AD201). Study subjects with MMSE scores between 16 and 26 received ELND005 oral doses of 250 mg, 1000 mg or 2000 mg twice daily or matching placebo. The study's cognitive (NTB) and functional (ADCS-ADL) co - primary endpoints did not achieve statistical significance.
› Verified 3 days ago
| Entity Name | Wellstone, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407809213 PECOS PAC ID: 9739070046 Enrollment ID: O20040324000453 |
News Archive
Asynt has introduced new reaction inserts for its DrySyn Heating Block range enabling scientists to now conduct precisely controlled heated/stirred experiments in 3 Dram vials, 20ml Scintillation vials and 2ml HPLC sample vials. The new multi position blocks when combined with a DrySyn base unit allow up to 27 experiments to be performed in parallel.
Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer.
The ability to tactually recognize fine spatial details, such as the raised dots used in braille, is especially important to those who are blind.
A team of researchers led by Kath Bogie, DPhil (PhD), a biomedical engineer and associate professor of orthopaedics and biomedical engineering at Case Western Reserve University School of Medicine, and colleagues from Case Western Reserve and other institutions, has received a $1.8M, three-year grant from the U.S. Department of Defense to develop an implantable muscle stimulator for preventing pressure ulcers and deep tissue injuries to the buttocks.
Elan Corporation, plc and Transition Therapeutics, Inc today announced the results of a Phase 2 placebo-controlled study in 351 patients with mild to moderate Alzheimer's disease who received study drug for up to 18 months (Study AD201). Study subjects with MMSE scores between 16 and 26 received ELND005 oral doses of 250 mg, 1000 mg or 2000 mg twice daily or matching placebo. The study's cognitive (NTB) and functional (ADCS-ADL) co - primary endpoints did not achieve statistical significance.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Erin Dover, LICSW 1909 Commerce Ave, Cullman, AL 35055-6151 Ph: () - | Erin Dover, LICSW 1909 Commerce Ave, Cullman, AL 35055-6151 Ph: (256) 734-4688 |
News Archive
Asynt has introduced new reaction inserts for its DrySyn Heating Block range enabling scientists to now conduct precisely controlled heated/stirred experiments in 3 Dram vials, 20ml Scintillation vials and 2ml HPLC sample vials. The new multi position blocks when combined with a DrySyn base unit allow up to 27 experiments to be performed in parallel.
Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer.
The ability to tactually recognize fine spatial details, such as the raised dots used in braille, is especially important to those who are blind.
A team of researchers led by Kath Bogie, DPhil (PhD), a biomedical engineer and associate professor of orthopaedics and biomedical engineering at Case Western Reserve University School of Medicine, and colleagues from Case Western Reserve and other institutions, has received a $1.8M, three-year grant from the U.S. Department of Defense to develop an implantable muscle stimulator for preventing pressure ulcers and deep tissue injuries to the buttocks.
Elan Corporation, plc and Transition Therapeutics, Inc today announced the results of a Phase 2 placebo-controlled study in 351 patients with mild to moderate Alzheimer's disease who received study drug for up to 18 months (Study AD201). Study subjects with MMSE scores between 16 and 26 received ELND005 oral doses of 250 mg, 1000 mg or 2000 mg twice daily or matching placebo. The study's cognitive (NTB) and functional (ADCS-ADL) co - primary endpoints did not achieve statistical significance.
› Verified 3 days ago